Common Stock that may be issuable upon exercise of warrants issued to Foris on July 29, 2015 and February 12, 2016. Foris is indirectly owned by John Doerr, who shares voting and investment control over the shares held by such entity. The address for Foris Ventures, LLC is 751 Laurel Street #717, San Carlos, California 94070. After giving pro forma effect to the full conversion of the shares of Preferred Stock issued in the Offering (which shares of Preferred Stock will, if not earlier converted, automatically convert to Common Stock on the 90
th
day following the date that the Stockholder Approval has been obtained and effected), assuming stockholder approval of Proposal 1, the number of shares of Common Stock beneficially owned by Foris as of April 30, 2017, and the Percent of Class, would have been 163,941,551 shares and 28.1%, respectively, including 73,160,764 shares issuable upon exercise of Cash Warrants held by Foris.
(5)
Shares beneficially owned by Mr. Melo include (i) 908,333 restricted stock units, all of which were unvested as of April 30, 2017, and (ii) 1,866,212 shares of Common Stock issuable upon exercise of options that were exercisable within 60 days of April 30, 2017.
(6)
Shares beneficially owned by Mr. Doerr include (i) 17,620,023 shares of Common Stock beneficially owned by Foris, in which Mr. Doerr indirectly owns all of the membership interests, (ii) 8,503 shares of Common Stock held by The Vallejo Ventures Trust U/T/A 2/12/96, of which Mr. Doerr is a trustee, (iii) 4,183,224 shares of Common Stock held by entities affiliated with Kleiner Perkins Caufield & Byers of which Mr. Doerr is an affiliate, excluding 246,007 shares over which Mr. Doerr has no voting or investment power, (iv) 17,000 restricted stock units, all of which were unvested as of April 30, 2017, and (v) 50,000 shares of Common Stock issuable upon exercise of options that were exercisable within 60 days of April 30, 2017.
(7)
Shares beneficially owned by Dr. Duyk include (i) 52,000 restricted stock units, all of which were unvested as of April 30, 2017, and (ii) 44,000 shares of Common Stock issuable upon exercise of options that were exercisable within 60 days of April 30, 2017.
(8)
Mr. Eykerman was appointed to the Board on May 18, 2017 as the designee of DSM International B.V., a subsidiary of Koninklijke DSM N.V. (together with its affiliates, “DSM”). Mr. Eykerman does not beneficially own any shares of Amyris Common Stock directly and disclaims beneficial ownership of all shares of Amyris Common Stock that are or may be beneficially owned by DSM. After giving pro forma effect to the full conversion of the shares of Preferred Stock issued in the Offering (which shares of Preferred Stock will, if not earlier converted, automatically convert to Common Stock on the 90
th
day following the date that the Stockholder Approval has been obtained and effected), assuming stockholder approval of Proposal 1, the number of shares of Common Stock beneficially owned by DSM as of April 30, 2017, and the Percent of Class, would have been 119,043,480 shares and 21.1%, respectively, including 59,521,740 shares issuable upon exercise of Cash Warrants held by DSM.
(9)
Shares beneficially owned by Mr. Klaeijsen include (i) 17,000 restricted stock units, all of which were unvested as of April 30, 2017, and (ii) 19,333 shares of Common Stock issuable upon exercise of options that were exercisable within 60 days of April 30, 2017. Mr. Klaeijsen was designated to serve as our director by Maxwell. Mr. Klaeijsen disclaims beneficial ownership of all shares of Amyris Common Stock that are or may be beneficially owned by Maxwell or any of its affiliates.
(10)
Shares beneficially owned by Ms. Piwnica include (i) 17,000 restricted stock units, all of which were unvested as of April 30, 2017, and (ii) 50,000 shares of Common Stock issuable upon exercise of options that were exercisable within 60 days of April 30, 2017. Ms. Piwnica is Director of NAXOS UK, a consulting firm advising private equity and was designated to serve as our director by Naxyris S.A. (“Naxyris”), an investment vehicle owned by Naxos Capital Partners SCA Sicar. NAXOS UK is affiliated with Naxos Capital Partners SCA Sicar. Ms. Piwnica disclaims beneficial ownership of all shares of Amyris Common Stock that are or may be beneficially owned by Naxyris. After giving pro forma effect to the full conversion of the shares of Preferred Stock issued in the Offering (which shares of Preferred Stock will, if not earlier converted, automatically convert to Common Stock on the 90
th
day following the date that the Stockholder Approval has been obtained and effected), assuming stockholder approval of Proposal 1, the number of shares of Common Stock beneficially owned by Naxyris as of April 30, 2017, and the Percent of Class, would have been 19,505,140 shares and 3.8%, respectively, including 5,556,038 shares issuable upon exercise of Cash Warrants held by Naxyris.